1. China Stocks

  2. •

    Commercial services

  3. •

    Miscellaneous commercial services
WuXi XDC Cayman, Inc.

WuXi XDC Cayman, Inc.

7.85
EUR
-0.80
(-9.25%)
8.41BMarket Cap
Mar 29Next Earn
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.08
0.26
0.84
2.08
3.38
4.89
- -
Basic EPS, GAAP
0.02
0.05
0.13
0.28
0.89
1.22
- -
Free Cash Flow per Basic Share
-0.03
0.01
0.04
-0.2
-0.66
0.43
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.32
0.02
1.26
4.55
5.53
8.54
8.54
Tangible Book Value per Share
0.31
-0.22
1.03
4.33
5.32
8.33
8.33
Basic Weighted Avg Shares
1,178
1,178
1,178
1,023
1,198
1,216
1,216
Sales/Revenue/Turnover
96
311
990
2,124
4,052
5,944
- -
Operating Margin (%)
34.53
19.33
14.3
18.92
23.41
28.11
- -
Depreciation Expense
13
19
31
60
110
148
- -
Net Income, GAAP
26
55
156
284
1,070
1,480
- -
Effective Tax Rate (%)
18.74
17.83
20.46
21.15
12.31
14.75
- -
Profit Margin (%)
27.29
17.65
15.72
13.35
26.4
24.91
- -
Working Capital
68
-608
388
3,921
3,635
6,398
6,398
LT Debt
- -
- -
2
2
15
32
32
Total Equity
376
21
1,481
5,454
6,639
10,725
10,725
Return on Invested Capital (%)
- -
23.42
14.4
7.87
13.15
14.84
- -
Return on Capital (%)
- -
26.28
19.71
8.1
17.03
15.95
- -
Return on Common Equity (%)
- -
27.7
20.74
8.18
17.69
17.05
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
481
1,023
847
LT Borrowings
- -
- -
- -
LT Finance Leases
15
16
32
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,200
1,203
1,255
Market Capitalization
34,466
46,718
69,127

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
6,101
6,952
10,063
Cash, Cash Equivalents & STI
3,973
4,538
7,464
Accounts Receivable, Net
1,573
1,721
1,822
Inventories
119
182
173
Total Current Liabilities
2,466
3,162
3,666
Payables & Accruals
- -
- -
- -
ST Debt
481
1,023
847
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
1,449.74%
61.54%
Free Cash Flow
- -
16.14%
-166.44%
Net Income, GAAP
- -
138.02%
38.41%
Sales/Revenue/Turnover
- -
138.63%
46.69%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
2,124
2024
- -
- -
4,052
2025
- -
- -
5,944

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.28
2024
- -
- -
0.89
2025
- -
- -
1.22

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jin Cai Li
Full Time Employees
2,662
Sector
Commercial services
Industry
Miscellaneous commercial services
Address
No. 11 Xinhui Ring Road Wuxi City JS China
IPO Date
Nov 17, 2023
Website
wuxixdc.com
Similar Companies
PayPal Holdings, Inc. (NASDAQ:PYPL)
Shopify Inc. (NASDAQ:SHOP)
Greenland Mines Ltd (NASDAQ:GRML)
Block, Inc. (NYSE:XYZ)
Netcapital Inc. (NASDAQ:NCPL)
Shopify, Inc. Class A (TSX:SHOP)
Business
WuXi XDC Cayman Inc. is a leading global contract research, development and manufacturing organization focused on antibody drug conjugates and other bioconjugates. The company provides end-to-end services including discovery, process development and GMP manufacturing of bioconjugate drug substances and drug products; monoclonal antibody intermediates; payload-linkers associated with bioconjugates; and antibody intermediates and other biologics intermediates, supported by proprietary technology platforms such as the upgraded WuXiDARx and novel WuXiTecan-1 and WuXiTecan-2 linker-payload technologies. Founded in 2013 and headquartered in Wuxi, China, it operates facilities in China, North America, Europe and internationally, including a new Singapore site that achieved mechanical completion in June 2025 with GMP manufacturing planned for 2026, serving 419 customers worldwide as a subsidiary of WuXi Biologics (Cayman) Inc. Recent developments include the GMP release of its DP3 drug product facility at the Wuxi site in July 2025 to scale manufacturing capacity; a strategic partnership with IntoCell announced in early 2024 for drug-linker technologies and integrated CRDMO services; a memorandum of understanding with Standard Chartered China in November 2025 for financial collaboration; signing 37 new integrated projects and adding three process performance qualification projects in the first half of 2025; and share placements in September 2025 raising HK$2.71 billion to support expansion.